

4th edition

# Compounding Sterile Preparations

*E. Clyde Buchanan, RPh, MS, FASHP*

Senior Director of Pharmacy (Ret.)  
Emory Healthcare  
Atlanta, Georgia

*Philip J. Schneider, MS, FASHP, FFIP, FASPEN*

Professor and Associate Dean for Academic &  
Professional Affairs  
University of Arizona College of Pharmacy  
Phoenix Biomedical Campus  
Phoenix, Arizona

*Ryan A. Forrey, PharmD, MS, FASHP*

Senior Manager, Market Development for  
Hazardous Drug Safety  
Becton, Dickinson and Company  
Franklin Lakes, New Jersey

Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 4500 East-West Highway, Suite 900, Bethesda, MD 20814, attention: Special Publishing.

The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product.

The authors would like to acknowledge the contributions of The U.S. Pharmacopeial Convention (USP), including allowing the generous references throughout this book to the *United States Pharmacopeia* and the *National Formulary (USP–NF)*. At the time of publishing, *USP 39–NF 34* (2016) is the current version of the *USP–NF*; however, references herein have also been made to *USP 32–NF 27* (2009), *USP 36–NF 31* (2013), and *USP 39–NF 34* First Supplement (2016) as indicated in the copyright notice for each *USP–NF* excerpt.

The presentation and interpretation of *USP–NF* provided by the authors do not necessarily reflect the views of USP or the requirements of *USP–NF*, and readers should be aware that all of USP's standards are subject to revision.

Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.

Editorial Project Manager, Books and eLearning Courses: Ruth Bloom

Editorial Project Manager, Publications Production Center: Kristin Eckles

Cover and Page Design: David Wade

Composition: Carol Barrer

#### Library of Congress Cataloging-in-Publication Data

Names: Buchanan, E. Clyde, editor. | Schneider, Philip J., editor. | Forrey, Ryan A., editor. | American Society of Health-System Pharmacists, issuing body.

Title: Compounding sterile preparations / [edited by] E. Clyde Buchanan, Philip J. Schneider, Ryan A. Forrey.

Description: Fourth edition. | Bethesda, MD : American Society of Health-System Pharmacists, [2017] | Includes bibliographical references and index.

Identifiers: LCCN 2017001193 | ISBN 9781585284849

Subjects: | MESH: Technology, Pharmaceutical--standards | Drug Compounding--standards | Sterilization--standards | Drug Contamination--prevention & control

Classification: LCC RS199.S73 | NLM QV 778 | DDC 615/.19--dc23 LC record available at <https://lccn.loc.gov/2017001193>.

© 2018, American Society of Health-System Pharmacists, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists.

ASHP is a service mark of the American Society of Health-System Pharmacists, Inc.; registered in the U.S. Patent and Trademark Office.

ISBN: 978-1-58528-484-9

10 9 8 7 6 5 4 3 2 1

*This edition is dedicated to the victims of the fungal meningitis outbreak of 2012, who serve as an enduring reminder of the consequences of poor compounding practice.*

*E. Clyde Buchanan*

*Philip J. Schneider*

*Ryan A. Forrey*



## TABLE OF CONTENTS

---

Acknowledgments.....	ix
Preface.....	xi
Contributors .....	xiii
Reviewers .....	xv

### Part I Sterile Preparation

1 Imperative for Change: Adverse Sterile Compounding Events.....	1
<i>Phillip J. Schneider, MS, FASHP, FFIP, FASPEN</i>	
2 Standards for Compounded Sterile Preparations .....	7
<i>E. Clyde Buchanan, RPh, MS, FASHP</i>	
3 Immediate-Use Compounding .....	35
<i>Jeannell M. Mansur, PharmD, RPh, FASHP</i>	
4 Sterile Preparation Formulation .....	51
<i>Mark G. Klang, RPh, MS, BCNSP, PhD</i>	
5 Parenteral Nutrition Compounding .....	67
<i>Todd W. Canada, PharmD, BCNSP, BCCCP, FASHP, FTSHP</i>	
6 Special Considerations in Pediatric Compounding.....	81
<i>Kathleen M. Gura, PharmD, BCNSP, FASHP, FPPAG, FASPEN</i>	
7 Special Considerations in Compounding Biologicals.....	113
<i>Susan Spivey, PharmD; Kelley Reece, PharmD; and Ryan K. Roux, PharmD, MS, RPh, FASHP</i>	
8 Ancillary Equipment and Supplies .....	121
<i>Ryan A. Forrey, PharmD, MS, FASHP</i>	
9 Primary Engineering Controls.....	133
<i>Richard C. Capps, PharmD</i>	
10 Personnel Cleansing and Garbing.....	153
<i>Richard B. Osteen, DPh</i>	
11 Aseptic Technique .....	161
<i>Linda F. McElhiney, PharmD, MSP, RPh, FIACP, FASHP, FACA</i>	
12 Handling and Compounding Hazardous Drugs.....	171
<i>Luci A. Power, RPh, MS and Joseph W. Coyne, BS Pharm, RPh</i>	
13 Radiopharmaceuticals As Compounded Sterile Preparations .....	203
<i>George H. Hinkle, RPh, MS, BCNP</i>	

14	Storage and Beyond-Use Dating.....	213
	<i>Caryn Dellamorte Bing, RPh, MS, FASHP</i>	
15	Labeling Sterile Preparations .....	227
	<i>Patricia Kuban, RPh, MBA</i>	
16	Documentation of Compounded Sterile Preparations .....	243
	<i>Ryan A. Forrey, PharmD, MS, FASHP</i>	
17	Sterility Assurance of Compounded Sterile Preparations .....	249
	<i>Angela W. Yaniv, PharmD</i>	
18	Finished Preparation Release Checks and Tests.....	257
	<i>Angela W. Yaniv, PharmD</i>	
19	Microbiological Issues in Compounding Sterile Preparations .....	267
	<i>Keith H. St. John, MT(ASCP), MS, CIC, FAPIC and Radhakrishna S. Tirumalai, PhD</i>	
20	Handling Sterile Commercial Products and Compounded Sterile Preparations within the Pharmacy .....	283
	<i>Ryan A. Forrey, PharmD, MS, FASHP</i>	
21	Maintaining Sterility, Purity, and Stability of Dispensed and Distributed CSPs .....	295
	<i>Caryn Dellamorte Bing, RPh, MS, FASHP</i>	
22	Batch Compounding.....	303
	<i>Richard B. Osteen, DPh</i>	
 <b>Part II QUALITY MANAGEMENT</b>		
23	Pharmacist Education .....	315
	<i>Phillip J. Schneider, MS, FASHP, FFIP, FASPEN</i>	
24	Pharmacy Technician Education, Certification, Training, Evaluation, and Regulation....	323
	<i>Mary Ann Stuhan, PharmD, RPh</i>	
25	Secondary Engineering Controls.....	333
	<i>E. Clyde Buchanan, RPh, MS, FASHP</i>	
26	Sterile Compounding Technology .....	363
	<i>Bruce A. Erickson, RPh, MS and Craig Boyce, RPh</i>	
27	Cleaning and Disinfecting .....	409
	<i>Ryan A. Forrey, PharmD, MS, FASHP</i>	
28	Environmental Quality and Control.....	425
	<i>Patricia C. Kienle, RPh, MPA, FASHP</i>	
29	Dealing with Latex Allergies .....	437
	<i>Stephen K. Hetey, RPh, MS, FASHP</i>	
30	Personnel Training and Competency Evaluation of Garbing and Aseptic Work Practices.....	445
	<i>Linda F. McElhiney, PharmD, MSP, RPh, FIACP, FASHP, FACA</i>	
31	Policies, Procedures, and Quality Assurance Programs .....	453
	<i>Patricia C. Kienle, RPh, MPA, FASHP</i>	
32	Outsourcing the Compounding of Sterile Preparations .....	473
	<i>E. Clyde Buchanan, RPh, MS, FASHP</i>	

---

**APPENDIXES**

Appendix A: ASHP Guidelines on Compounding Sterile Preparations ..... 489

Appendix B: ASHP Guidelines on Handling Hazardous Drugs..... 517

Appendix C: Selected ASHP Guidelines Pertaining to Sterile Compounding ..... 545

Appendix D: Selected Websites Pertaining to Compounding Sterile Preparations ..... 547

  

Glossary ..... 551

Index ..... 567





## ACKNOWLEDGMENTS

---

Every day many pharmacists and pharmacy technicians participate in compounding sterile preparations. In the vast majority of cases, their preparations are accurate, stable, pure, and sterile. We salute these health professionals who maintain essential high standards. Such work requires great attention to detail and genuine care for patients.

We are grateful to Ruth Bloom, Beth Campbell, Kristin Eckles, and the many other ASHP staff members who reviewed and edited each chapter of this text. We express special gratitude to Jack Bruggeman, former ASHP Director of Special

Publishing, who began working with us on this book in 2014. Without his encouragement and support, our work would not have been possible.

Finally, to our family members and friends who gave us the space and emotional support to finish, we express our heartfelt appreciation.

*E. Clyde Buchanan*  
*Philip J. Schneider*  
*Ryan A. Forrey*



This professional reference for pharmacists and pharmacy technicians who compound sterile preparations also will serve well as a textbook for student pharmacists and pharmacy technicians. To assist with classroom use, ASHP plans to publish learning objectives and review questions and answers for each chapter. There is a robust list of references at the end of each chapter for those scholars who wish to dig deeper into this rich material.

Since the current version of USP Chapter <797> Pharmaceutical Compounding—Sterile Preparations became official in June 2008, much has happened in the world of sterile compounding. Perhaps the most significant event, as well as the most tragic, was the multistate outbreak of fungal meningitis and other infections that occurred in 2012 ([www.cdc.gov](http://www.cdc.gov)). The Centers for Disease Control and Prevention (CDC) counted 753 infected patients in 20 states, and 64 of those infected patients died. Contaminated steroid injections compounded at the New England Compounding Center in Framingham, Massachusetts, caused these infections. As a direct consequence, in 2013 the U.S. Congress passed the Drug Quality and Security Act (DQSA) to be enforced by the Food and Drug Administration. The meningitis outbreak also sparked concerns about compounding pharmacies and prompted an investigation by the Office of the Inspector General (OIG) regarding the use of compounding pharmacies by hospitals and oversight of hospital compounding by the Centers for Medicare & Medicaid Services (CMS) and its accrediting organizations (OIG report OEI-01-13-00400). The OIG recommended that accreditation surveyors be trained on

standards for safe compounding practices and that CMS amend its interpretive guidelines to address hospitals' contracts with standalone compounding pharmacies. In October 2015, CMS did so. In May 2016, one of the CMS accreditation agencies, the Healthcare Facilities Accreditation Program, published updates to its pharmaceutical standards. These standards identify extensive and specific requirements for compounded sterile preparations. The other agencies that accredit pharmacies and healthcare organizations will update their pharmacy standards too.

In February 2016, the *United States Pharmacopeia* finalized USP Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. This enforceable chapter applies to all healthcare personnel and entities that handle hazardous drugs. *Compounding Sterile Preparations, Fourth Edition*, updates all chapters for DQSA and USP Chapter <800> but refers to the 2008 version of USP Chapter <797>, which is current as of this publication. The fourth edition does not cover USP Chapter <797> proposed in late 2015 which is still under review and revision. When a new, final USP Chapter <797> becomes available, ASHP will publish a revised edition.

All previous chapters have been updated, and several new chapters and chapter authors have been added. New chapters include the following:

- Imperative for Change: Adverse Sterile Compounding Events
- Immediate-Use Compounding
- Special Considerations in Pediatric Compounding

- Special Considerations in Compounding Biologicals
- Microbiological Issues in Compounded Sterile Preparations
- Sterile Compounding Technology

New authors include Craig A. Boyce, Todd W. Canada, Richard C. Capps, Bruce A. Erickson, Ryan A. Forrey, Kathleen M. Gura, Patricia C. Kienle, Mark G. Klang, Jeannell M. Mansur, Linda F. McElhiney, Richard B. Osteen, Kelley Reece, Ryan K. Roux, Keith H. St. John, Susan Spivey, Mary Ann Stuhan, Radhakrishna S. Tirumalai, and Angela W. Yaniv. All chapter authors are listed with their credentials in the front matter and anyone who compounds sterile preparations will recognize the experts assembled for this work.

With all the new material, we needed another coeditor, so we are fortunate to welcome Ryan A. Forrey and his expertise. Having served as the Associate Director of Pharmacy and Infusion Services

at the Ohio State University Wexner Medical Center and as the Director of Pharmacy at Emory University Hospital Midtown, he is now Senior Manager for Market Development of Hazardous Drug Safety at Becton, Dickinson and Company. Dr. Forrey is also on the Compounding Expert Committee for the *United States Pharmacopeia*.

Many challenges face the pharmacy staff members who compound sterile preparations. Let us meet those challenges by providing our patients with the safest compounded sterile preparations possible and protecting the healthcare employees who handle hazardous drugs. Our professional reputation depends on it.

*E. Clyde Buchanan*  
*Philip J. Schneider*  
*Ryan A. Forrey*  
September 2017

## CONTRIBUTORS

---

**Caryn Dellamorte Bing, RPh, MS, FASHP**  
Co-Editor, *Extended Stability for Parenteral  
Drugs*  
CB Healthcare Consulting  
Las Vegas, Nevada

**Craig A. Boyce, RPh**  
Pharmacy Systems Consultant  
ARxIUM Inc.  
Buffalo Grove, Illinois

**E. Clyde Buchanan, RPh, MS, FASHP**  
Senior Director of Pharmacy (Ret.)  
Emory Healthcare  
Atlanta, Georgia

**Todd W. Canada, PharmD, BCNSP, BCCCP,  
FASHP, FTSHP**  
Clinical Pharmacy Services Manger &  
Nutrition Support Team Coordinator  
Division of Pharmacy  
University of Texas MD Anderson Cancer  
Center  
Houston, Texas

**Richard C. Capps, PharmD**  
Manager of Pharmacy Operations  
GHS Oconee Memorial Hospital  
Seneca, South Carolina

**Joseph W. Coyne, BS Pharm, RPh**  
Director of Field Operations  
Clinical IQ, LLC  
Mundelein, Illinois

**Bruce A. Erickson, RPh, MS**  
Pharmacy Automation Consultant (Ret.)  
Director of Pharmacy (Ret.)  
VA Medical Center, Minneapolis  
Placida, Florida

**Ryan A. Forrey, PharmD, MS, FASHP**  
Senior Manager, Market Development for  
Hazardous Drug Safety  
Becton, Dickinson and Company  
Franklin Lakes, New Jersey

**Kathleen M. Gura, PharmD, BCNSP, FASHP,  
FPPAG, FASPEN**  
Pharmacy Clinical Research Program  
Manager  
Clinical Pharmacist, Gastroenterology/  
Nutrition  
Boston Children's Hospital  
Assistant Professor of Pediatrics  
Harvard Medical School  
Boston, Massachusetts

**Stephen K. Hetey, RPh, MS, FASHP**  
Associate Chief Pharmacy Officer (Ret.)  
Department of Pharmacy  
Duke Children's Hospital and Health Center  
Duke University Medical Center and Health  
System  
Durham, North Carolina

**George H. Hinkle, RPh, MS, BCNP**  
University Radiation Safety Officer  
Radiation Safety Section—Environmental  
Health & Safety  
Faculty Emeritus  
Pharmacy Practice and Science  
The Ohio State University  
Columbus, Ohio

**Patricia C. Kienle, RPh, MPA, FASHP**  
Director, Accreditation and Medication  
Safety  
Cardinal Health Innovative Delivery  
Solutions  
Laflin, Pennsylvania

**Mark G. Klang, RPh, MS, BCNSP, PhD**  
Core Manager, Research Pharmacy  
Memorial Sloan Kettering Cancer Center  
New York, New York

**Patricia Kuban, RPh, MBA**  
Director of Pharmaceutical Services  
Emory University Hospital, Emory  
University Orthopaedics and Spine  
Hospital, and Emory Wesley Woods  
Hospital  
Atlanta, Georgia

**Jeannell M. Mansur, PharmD, RPh, FASHP**  
Principal Consultant  
Medication Management and Safety  
Joint Commission Resources/Joint  
Commission International  
Oak Brook, Illinois

**Linda F. McElhiney, PharmD, MSP, RPh,  
FIACP, FASHP, FACA**  
Compounding Pharmacist  
Indiana University Health  
Indianapolis, Indiana

**Richard B. Osteen, DPh**  
Sterile Products Manager  
Vanderbilt University Medical Center  
Nashville, Tennessee

**Luci A. Power, RPh, MS**  
Senior Pharmacy Consultant  
Power Enterprises  
San Francisco, California

**Kelley Reece, PharmD**  
Assistant Pharmacy Manager  
The University of Texas MD Anderson  
Cancer Center  
Houston, Texas

**Ryan K. Roux, PharmD, MS, RPh, FASHP**  
Director of Pharmacy Operations  
The University of Texas MD Anderson  
Cancer Center  
Houston, Texas

**Philip J. Schneider, MS, FASHP, FFIP, FASPEN**  
Professor and Associate Dean for Academic  
& Professional Affairs  
University of Arizona College of Pharmacy  
Phoenix Biomedical Campus  
Phoenix, Arizona

**Susan Spivey, PharmD**  
Pharmacy Manager  
The University of Texas MD Anderson  
Cancer Center  
Houston, Texas

**Keith H. St. John, MT(ASCP), MS, CIC, FAPIC**  
Vice President, Clinical Affairs  
PDI Infection Prevention  
Orangeburg, New York

**Mary Ann Stuhan, PharmD, RPh**  
Pharmacy Program Manager  
Cuyahoga Community College  
Highland Hills, Ohio

**Radhakrishna S. Tirumalai, PhD**  
Microbiology Professional  
North Potomac, Maryland

**Angela W. Yaniv, PharmD**  
Assistant Director for Sterile Products  
Cleveland Clinic  
Cleveland, Ohio

## REVIEWER

---

*Lisa D. Ashworth, BS Pharm, RPh, FACA*  
Compounding Specialist and Clinical  
Pharmacist (All Campuses)  
Children's Health  
Dallas, Texas





# Part I:

# Sterile Preparation

1	Imperative for Change: Adverse Sterile Compounding Events .....	1
2	Standards for Compounded Sterile Preparations.....	7
3	Immediate-Use Compounding .....	35
4	Sterile Preparation Formulation .....	51
5	Parenteral Nutrition Compounding .....	67
6	Special Considerations in Pediatric Compounding .....	81
7	Special Considerations in Compounding Biologicals.....	113
8	Ancillary Equipment and Supplies .....	121
9	Primary Engineering Controls .....	133
10	Personnel Cleansing and Garbing .....	153
11	Aseptic Technique .....	161
12	Handling and Compounding Hazardous Drugs .....	171
13	Radiopharmaceuticals as Compounded Sterile Preparations.....	203
14	Storage and Beyond-Use Dating .....	213
15	Labeling Sterile Preparations.....	227
16	Documentation of Compounded Sterile Preparations.....	243
17	Sterility Assurance of Compounded Sterile Preparations.....	249
18	Finished Preparation Release Checks and Tests .....	257
19	Microbiological Issues in Compounding Sterile Preparations.....	267
20	Handling Sterile Commercial Products and Compounded Sterile Preparations within the Pharmacy.....	283
21	Maintaining Sterility, Purity, and Stability of Dispensed and Distributed CSPs.....	295
22	Batch Compounding .....	303

